

# Vinay K Puduvalli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1627423/publications.pdf>

Version: 2024-02-01

57  
papers

2,149  
citations

279798

23  
h-index

233421

45  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. <i>Neuro-Oncology</i> , 2022, 24, 229-244.	1.2	13
2	Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 1979-1990.	7.0	10
3	Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. <i>Radiotherapy and Oncology</i> , 2022, , .	0.6	0
4	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab186.	0.7	1
5	Management of gliomas in patients with Lynch syndrome. <i>Neuro-Oncology</i> , 2021, 23, 167-168.	1.2	5
6	Demystifying demethylator sensitivity in gliomas: role for TERT and DNMT1. <i>Neuro-Oncology</i> , 2021, 23, 7-8.	1.2	0
7	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. <i>Neuro-Oncology</i> , 2021, 23, 1252-1260.	1.2	11
8	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 679702.	2.8	8
9	Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab079.	0.7	6
10	Targeted Therapy for BRAF Mutant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 105.	3.0	4
11	Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab141.	0.7	3
12	Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. <i>The Journal of Breast Health</i> , 2021, 17, 371-377.	1.0	4
13	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1505-1515.	1.2	27
14	Early imaging marker of progressing glioblastoma: a window of opportunity. <i>Journal of Neuro-Oncology</i> , 2020, 148, 629-640.	2.9	3
15	Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. <i>PLoS ONE</i> , 2020, 15, e0244383.	2.5	15
16	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
17	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	2.8	3
18	Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation. <i>World Neurosurgery</i> , 2019, 128, 381-384.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 242-255.	5.2	38
20	Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Cancer</i> , 2019, 125, 424-433.	4.1	46
21	Chemotherapy of High-Grade Astrocytomas in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 116-144.	1.3	5
22	Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 351-366.	6.7	16
23	Highlighting Advances in the Treatment of Gliomas. <i>Oncology Times</i> , 2017, 39, 1,17-18.	0.1	1
24	Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. <i>Clinical Cancer Research</i> , 2017, 23, 6215-6226.	7.0	53
25	EXTH-84. TARGETING THE SALVAGE PATHWAY OF NAD+ GENERATION IN GLIOMAS BY KPT-9274, A NOVEL DUAL INHIBITOR OF PAK4 AND NAMPT. <i>Neuro-Oncology</i> , 2017, 19, vi91-vi91.	1.2	0
26	Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. <i>Neuro-Oncology</i> , 2016, 18, 1209-1218.	1.2	75
27	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 487-494.	2.9	52
28	Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. <i>Journal of Neuro-Oncology</i> , 2016, 126, 527-533.	2.9	13
29	CHARACTERIZATION OF THE ACTIVITY OF AT13387, A NOVEL SECOND GENERATION HSP90 INHIBITOR AGAINST GLIOMAS. <i>Neuro-Oncology</i> , 2015, 17, v19.1-v19.	1.2	2
30	ANGI-06PAK4 GOVERNS RADIATION-INDUCED ENDOTHELIAL Gro-1±CXCR2 SIGNALING AND ANGIOGENESIS IN GLIOMA. <i>Neuro-Oncology</i> , 2015, 17, v42.1-v42.	1.2	0
31	Adult brainstem gliomas: Correlation of clinical and molecular features. <i>Journal of the Neurological Sciences</i> , 2015, 353, 92-97.	0.6	44
32	International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2015, 2, 62-69.	1.6	18
33	Standardized orthotopic xenografts in zebrafish reveal glioma cell line specific characteristics and tumor cell heterogeneity. <i>DMM Disease Models and Mechanisms</i> , 2015, 9, 199-210.	2.4	42
34	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 266-273.	1.2	61
35	Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?. <i>Journal of Neuro-Oncology</i> , 2015, 123, 141-150.	2.9	85
36	Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 823-828.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0
38	Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. Clinical Cancer Research, 2012, 18, 6032-6039.	7.0	56
39	Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer, 2012, 118, 3599-3606.	4.1	13
40	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. Journal of Neuro-Oncology, 2011, 102, 273-280.	2.9	26
41	Papillary endothelial hyperplasia presenting as recurrent malignant glioma. Journal of Neuro-Oncology, 2011, 102, 491-498.	2.9	4
42	Progressive multifocal leukoencephalopathy in a patient with glioblastoma. Journal of Neuro-Oncology, 2011, 103, 791-796.	2.9	8
43	Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. Journal of Neuro-Oncology, 2011, 105, 241-251.	2.9	37
44	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	1.6	450
45	Aberrations of the Epigenome in Gliomas: Novel Targets for Therapy. , 2010, , 185-202.		1
46	Chemotherapy as first line treatment for oligodendroglioma. Journal of Neuro-Oncology, 2008, 86, 361-362.	2.9	0
47	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-Oncology, 2008, 10, 216-222.	1.2	52
48	Temozolomide and Resistant Glioma Cells. Journal of Neurosurgery, 2008, 108, 197.	1.6	1
49	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2007, 81, 271-277.	2.9	61
50	Induction of Apoptosis in Primary Meningioma Cultures by Fenretinide. Cancer Research, 2005, 65, 1547-1553.	0.9	39
51	Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2004, 22, 4282-4289.	1.6	79
52	Inhibition of Angiogenesis as a Therapeutic Strategy against Brain Tumors. Cancer Treatment and Research, 2004, 117, 307-336.	0.5	26
53	Management of Patients with Brain Metastasis. , 2004, , 31-48.		0
54	Brain metastasis from prostate carcinoma. Cancer, 2003, 98, 363-368.	4.1	204

#	ARTICLE	IF	CITATIONS
55	Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival. <i>Oncology</i> , 2003, 65, 259-266.	1.9	72
56	Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. <i>Neuro-Oncology</i> , 2002, 4, 268-277.	1.2	41
57	Brain metastases: Biology and the role of the brain microenvironment. <i>Current Oncology Reports</i> , 2001, 3, 467-475.	4.0	30